iRhythm HoldingsIRTC +2.01%75 FCF Margin % is -16.59% as of Mar. 2026. GuruFocus rates IRTC with a GF Score™ of 75/100 and a GF Value™ of $162.87 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, iRhythm Holdings ranks better than 56.2% on this metric.
The historical rank and industry rank for iRhythm Holdings's FCF Margin % or its related term are showing as below:
IRTC'
s FCF Margin % Range Over the Past 10 Years
Min: -30.3 Med: -18.51 Max: 4.62
Current: 2.38
During the past 12 years, the highest FCF Margin % of iRhythm Holdings was 4.62%. The lowest was -30.30%. And the median was -18.51%.
IRTC's FCF Margin % is ranked better than 56.2% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs IRTC: 2.38
iRhythm Holdings FCF Margin % Related Terms
iRhythm Holdings FCF Margin % Historical Data
* Premium members only.
The historical data trend for iRhythm Holdings's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, iRhythm Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRhythm Holdings FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRhythm Holdings's FCF Margin % distribution charts can be found below:
* The bar in red indicates where iRhythm Holdings's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iRhythm Holdings (IRTC) has a FCF Margin % of -16.59% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on iRhythm Holdings and its competitors. According to the industry distribution chart, iRhythm Holdings ranks #357 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 43.8%.
Is iRhythm Holdings' FCF Margin % too high?
iRhythm Holdings' current FCF Margin % is -16.59%. Based on the distribution chart, iRhythm Holdings ranks #357 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, iRhythm Holdings has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iRhythm Holdings' FCF Margin % compare to LIVN and HAE?
According to the Medical Devices & Instruments industry distribution chart, iRhythm Holdings ranks #357 out of 815 companies for FCF Margin %. This puts iRhythm Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on iRhythm Holdings and its competitors. iRhythm Holdings's current FCF Margin % is -16.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRhythm Holdings stock overvalued right now?
Based on GuruFocus' analysis, iRhythm Holdings (IRTC) is currently considered Significantly Undervalued. The stock's GF Value™ is $162.87, compared to a current price of $114.73 — trading 29.6% below its estimated fair value. The current FCF Margin % is -16.59%. iRhythm Holdings' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For iRhythm Holdings (IRTC), the current FCF Margin % is -16.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRhythm Holdings (IRTC) Overvalued in 2026?
Based on GuruFocus' analysis, iRhythm Holdings stock appears to be undervalued.
The current stock price of $114.73 is trading 29.6% below its estimated GF Value™ of $162.87.
GuruFocus considers iRhythm Holdings to be Significantly Undervalued.
Key valuation signals for IRTC:
FCF Margin %: -16.59%
GF Value™: $162.87 vs. price of $114.73 (29.6% below fair value)
No single metric tells the full story. See the IRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
75GF Score
Get the complete analysis for IRTC
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRTC has been successfully added to your 
